• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Parenteral formulation of Flavopiridol (NSC-649890).

作者信息

Dannenfelser R M, Surakitbanharn Y, Tabibi S E, Yalkowsky S H

机构信息

University of Arizona, College of Pharmacy, Tucson, Arizona, USA.

出版信息

PDA J Pharm Sci Technol. 1996 Nov-Dec;50(6):356-9.

PMID:9038080
Abstract

Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6' -chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither cosolvency complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl beta-cyclodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen's phosphate buffer pH 7.4.

摘要

相似文献

1
Parenteral formulation of Flavopiridol (NSC-649890).
PDA J Pharm Sci Technol. 1996 Nov-Dec;50(6):356-9.
2
Solubilization of flavopiridol by pH control combined with cosolvents, surfactants, or complexants.
J Pharm Sci. 1999 Sep;88(9):945-7. doi: 10.1021/js990097r.
3
Solubilization of ionized and un-ionized flavopiridol by ethanol and polysorbate 20.乙醇和聚山梨醇酯20对离子化和非离子化黄酮哌啶醇的增溶作用。
J Pharm Sci. 1999 May;88(5):507-9. doi: 10.1021/js980433o.
4
Preformulation studies of myricetin: a natural antioxidant flavonoid.杨梅素的制剂前研究:一种天然抗氧化剂类黄酮
Pharmazie. 2014 Jan;69(1):19-26.
5
Combined effect of complexation and pH on solubilization.络合作用与pH值对增溶的联合效应
J Pharm Sci. 1998 Dec;87(12):1535-7. doi: 10.1021/js9801889.
6
Reformulation of a new vancomycin analog: an example of the importance of buffer species and strength.一种新型万古霉素类似物的重新配方:缓冲剂种类和强度重要性的一个实例
AAPS PharmSciTech. 2006 Jan 13;7(1):E5. doi: 10.1208/pt070105.
7
Stabilization of minodronic acid in aqueous solution for parenteral formulation.用于肠胃外制剂的水溶液中米诺膦酸的稳定性。
Int J Pharm. 2001 Jul 3;222(1):91-9. doi: 10.1016/s0378-5173(01)00704-9.
8
Buffer capacity and precipitation control of pH solubilized phenytoin formulations.pH 溶解型苯妥英制剂的缓冲容量和沉淀控制
Int J Pharm. 1999 Aug 5;185(1):45-9. doi: 10.1016/s0378-5173(99)00129-5.
9
Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection.采用反相液相色谱-电化学检测法测定人血浆中的黄酮哌醇(L86 8275;NSC 649890)。
Cancer Chemother Pharmacol. 1998;42(4):261-5. doi: 10.1007/s002800050815.
10
Solubilization and preformulation studies on PG-300995 (an anti-HIV drug).PG-300995(一种抗HIV药物)的增溶及处方前研究
J Pharm Sci. 2005 Feb;94(2):297-303. doi: 10.1002/jps.20246.

引用本文的文献

1
Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.近期治疗进展以及纳米技术、组合产品和免疫疗法在改变急性髓细胞白血病治疗格局中的作用。
Pharm Res. 2019 Jun 24;36(9):125. doi: 10.1007/s11095-019-2654-z.
2
A novel liposomal formulation of flavopiridol.一种新型的黄酮哌酯脂质体制剂。
Int J Pharm. 2009 Jan 5;365(1-2):170-4. doi: 10.1016/j.ijpharm.2008.08.008. Epub 2008 Aug 20.